Insider Transactions in Q1 2024 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
5,000
-39.98%
|
$725,000
$145.06 P/Share
|
|
Mar 21
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+28.56%
|
$515,000
$103.52 P/Share
|
|
Mar 14
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-37.44%
|
$10,425,000
$139.38 P/Share
|
|
Mar 14
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+24.63%
|
$6,000,000
$80.04 P/Share
|
|
Mar 14
2024
|
George J Morrow Director |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$5,560,000
$139.42 P/Share
|
|
Mar 14
2024
|
George J Morrow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$1,560,000
$39.79 P/Share
|
|
Mar 13
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
23,200
-44.01%
|
$3,248,000
$140.33 P/Share
|
|
Mar 13
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,200
+30.56%
|
$974,400
$42.76 P/Share
|
|
Mar 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
3,000
-28.55%
|
$420,000
$140.14 P/Share
|
|
Mar 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+22.21%
|
$318,000
$106.02 P/Share
|
|
Mar 11
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
100
-0.34%
|
$14,000
$140.0 P/Share
|
|
Mar 11
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.34%
|
$4,200
$42.76 P/Share
|
|
Mar 11
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
200
-2.6%
|
$28,000
$140.0 P/Share
|
|
Mar 11
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+2.53%
|
$21,200
$106.02 P/Share
|
|
Mar 08
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
1,700
-5.45%
|
$238,000
$140.05 P/Share
|
|
Mar 08
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+5.17%
|
$71,400
$42.76 P/Share
|
|
Mar 08
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
1,800
-19.34%
|
$252,000
$140.03 P/Share
|
|
Mar 08
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+16.21%
|
$190,800
$106.02 P/Share
|
|
Feb 29
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
273
-3.51%
|
$36,855
$135.51 P/Share
|
|
Feb 29
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
273
+3.39%
|
$21,567
$79.02 P/Share
|
|
Feb 28
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
6,544
-22.34%
|
$883,440
$135.42 P/Share
|
|
Feb 28
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,544
+18.18%
|
$516,976
$79.02 P/Share
|
|
Feb 28
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-45.83%
|
$10,050,000
$134.69 P/Share
|
|
Feb 28
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+31.05%
|
$4,575,000
$61.13 P/Share
|
|
Feb 27
2024
|
Leslie V Norwalk Director |
SELL
Open market or private sale
|
Direct |
8,000
-100.0%
|
$1,080,000
$135.67 P/Share
|
|
Feb 27
2024
|
Leslie V Norwalk Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
$672,000
$84.95 P/Share
|
|
Feb 20
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
15,000
-33.7%
|
$1,980,000
$132.47 P/Share
|
|
Feb 20
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.21%
|
$180,000
$12.98 P/Share
|
|
Feb 13
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,114
-4.49%
|
$147,048
$132.96 P/Share
|
|
Feb 13
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,098
-2.69%
|
$144,936
$132.99 P/Share
|
|
Feb 13
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,432
-9.84%
|
$189,024
$132.94 P/Share
|
|
Feb 13
2024
|
Kyle Gano Chief Business Development Off |
SELL
Open market or private sale
|
Direct |
1,352
-0.99%
|
$178,464
$132.89 P/Share
|
|
Feb 13
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,832
-0.55%
|
$376,656
$133.02 P/Share
|
|
Feb 13
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
796
-4.24%
|
$105,868
$133.04 P/Share
|
|
Feb 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
716
-8.71%
|
$95,228
$133.03 P/Share
|
|
Feb 13
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,098
-2.63%
|
$146,034
$133.01 P/Share
|
|
Feb 13
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,811
-14.56%
|
$240,863
$133.08 P/Share
|
|
Feb 13
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,352
-4.11%
|
$178,464
$132.85 P/Share
|
|
Feb 13
2024
|
Kevin Charles Gorman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,090
+0.5%
|
$198,510
$39.62 P/Share
|
|
Feb 08
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,328
-11.31%
|
$179,280
$135.49 P/Share
|
|
Feb 08
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,329
-3.64%
|
$179,415
$135.5 P/Share
|
|
Feb 08
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
911
-2.3%
|
$122,074
$134.24 P/Share
|
|
Feb 08
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
980
-4.14%
|
$131,320
$134.21 P/Share
|
|
Feb 08
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.45%
|
$304,716
$134.15 P/Share
|
|
Feb 08
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.41%
|
$131,320
$134.19 P/Share
|
|
Feb 08
2024
|
Kyle Gano Chief Business Development Off |
SELL
Open market or private sale
|
Direct |
980
-0.73%
|
$131,320
$134.2 P/Share
|
|
Feb 08
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
980
-3.13%
|
$131,320
$134.21 P/Share
|
|
Feb 06
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
456
-4.36%
|
$64,296
$141.96 P/Share
|
|
Feb 06
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,215
-3.34%
|
$172,530
$142.07 P/Share
|
|
Feb 06
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,041
-2.67%
|
$147,822
$142.17 P/Share
|